{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T08:46:47Z","timestamp":1788425207818,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ymgme.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T20:05:45Z","timestamp":1639425945000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations"],"prefix":"10.1016","volume":"135","author":[{"given":"D.","family":"van Vliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"van der Goot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.G.","family":"van Ginkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.R.","family":"van Faassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"de Blaauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.P.","family":"Kema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Heiner-Fokkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.A.","family":"van der Zee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2021.11.003_bb0005","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ymgme.2021.11.003_bb0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/jimd.12049","article-title":"Cerebrospinal fluid biogenic amines depletion and brain atrophy in adult patients with phenylketonuria","volume":"42","author":"Pilotto","year":"2019","journal-title":"J.\u00a0Inherit.\u00a0Metab.\u00a0Dis."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet J.Rare Dis."},{"issue":"9","key":"10.1016\/j.ymgme.2021.11.003_bb0020","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","article-title":"Key European guidelines for the diagnosis and management of patients with phenylketonuria","volume":"5","author":"van Spronsen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/archneur.1976.00500100018008","article-title":"Lowering brain phenylalanine levels by giving other large neutral amino acids. A new experimental therapeutic approach to phenylketonuria","volume":"33","author":"Andersen","year":"1976","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00711746","article-title":"Nutritional value of essential amino acids in the treatment of adults with phenylketonuria","volume":"18","author":"Dotremont","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0035","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1651-2227.2005.tb02078.x","article-title":"Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria","volume":"94","author":"Kalkanoglu","year":"2005","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1096-7192(03)00078-7","article-title":"Large neutral amino acid therapy and phenylketonuria: a promising approach to treatment","volume":"79","author":"Koch","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0045","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1542\/peds.112.S4.1570","article-title":"Future role of large neutral amino acids in transport of phenylalanine into the brain","volume":"112","author":"Matalon","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0050","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10545-006-0395-8","article-title":"Large neutral amino acids in the treatment of phenylketonuria (PKU)","volume":"29","author":"Matalon","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10545-007-0556-4","article-title":"Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine","volume":"30","author":"Matalon","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0060","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1542\/peds.112.S4.1575","article-title":"Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults","volume":"112","author":"Moats","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0065","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1172\/JCI5017","article-title":"Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria","volume":"103","author":"Pietz","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymgme.2007.02.002","article-title":"The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study","volume":"91","author":"Schindeler","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jpeds.2012.10.015","article-title":"Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker","volume":"162","author":"Yano","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0080","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpeds.2014.03.061","article-title":"Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation","volume":"165","author":"Yano","year":"2014","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/ejcn.2016.166","article-title":"Long-term treatment of phenylketonuria with a new medical food containing large neutral amino acids","volume":"71","author":"Concolino","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0090","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3390\/nu11102541","article-title":"Large neutral amino acid therapy increases tyrosine levels in adult patients with phenylketonuria: a long-term study","volume":"11","author":"Burlina","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0095","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3390\/nu12072078","article-title":"The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria","volume":"12","author":"Burlina","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0100","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/nu12041092","article-title":"Large neutral amino acids (LNAAs) supplementation improves neuropsychological performances in adult patients with phenylketonuria","volume":"12","author":"Scala","year":"2020","journal-title":"Nutrients"},{"issue":"Suppl 1","key":"10.1016\/j.ymgme.2021.11.003_bb0105","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.ymgme.2009.10.181","article-title":"Animal models of brain dysfunction in phenylketonuria","volume":"99","author":"Martynyuk","year":"2010","journal-title":"Mol. Genet. Metab."},{"issue":"5","key":"10.1016\/j.ymgme.2021.11.003_bb0110","first-page":"1292","article-title":"Therapeutic brain modulation with targeted large neutral amino acid supplements in the Pah-enu2 phenylketonuria mouse model","volume":"104","author":"van Vliet","year":"2016","journal-title":"Am.\u00a0J.\u00a0Clin.\u00a0Nutr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0115","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jnutbio.2017.09.020","article-title":"Large neutral amino acid supplementation as an alternative to the phenylalanine-restricted diet in adults with phenylketonuria: evidence from adult pah-enu2 mice","volume":"53","author":"van Vliet","year":"2018","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143833","article-title":"Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice","volume":"10","author":"van Vliet","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0125","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.3390\/nu11092252","article-title":"The benefit of large neutral amino acid supplementation to a liberalized phenylalanine-restricted diet in adult phenylketonuria patients: evidence from adult pah-Enu2 mice","volume":"11","author":"van Vliet","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0130","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1651-2227.1994.tb13025.x","article-title":"Unchanged MRI of myelin in adolescents with PKU supplied with non-phe essential amino acids after dietary relaxation","volume":"83","author":"Lou","year":"1994","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0140","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","article-title":"How practical are recommendations for dietary control in phenylketonuria?","volume":"360","author":"Walter","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0145","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/jn\/123.11.1939","article-title":"AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet","volume":"123","author":"Reeves","year":"1993","journal-title":"J. Nutr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0150","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10545-010-9216-1","article-title":"Large neutral amino acids in the treatment of PKU: from theory to practice","volume":"33","author":"van Spronsen","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0155","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1203\/00006450-198209000-00009","article-title":"Reduction of cerebrospinal fluid phenylalanine after oral administration of valine, isoleucine, and leucine","volume":"16","author":"Berry","year":"1982","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0160","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/archpedi.1990.02150290033020","article-title":"Valine, isoleucine, and leucine. A new treatment for phenylketonuria","volume":"144","author":"Berry","year":"1990","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-8749.1985.tb04522.x","article-title":"Preliminary support for the oral administration of valine, isoleucine and leucine for phenylketonuria","volume":"27","author":"Jordan","year":"1985","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0170","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/BF00441411","article-title":"Increased neurotransmitter biosynthesis in phenylketonuria induced by phenylalanine restriction or by supplementation of unrestricted diet with large amounts of tyrosine","volume":"148","author":"Lykkelund","year":"1988","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1440-1754.1997.tb01031.x","article-title":"Tyrosine supplementation in phenylketonuria","volume":"33","author":"Lines","year":"1997","journal-title":"J.\u00a0Paediatr.\u00a0Child Health"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0180","first-page":"51","article-title":"Effects of diet discontinuation and dietary tryptophan supplementation on neurotransmitter metabolism in phenylketonuria","volume":"1","author":"Nielsen","year":"1988","journal-title":"Brain Dysfunct."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0140-6736(85)90250-8","article-title":"Large doses of tryptophan and tyrosine as potential therapeutic alternative to dietary phenylalanine restriction in phenylketonuria","volume":"2","author":"Lou","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2021.11.003_bb0190","first-page":"1261","article-title":"Cognition and tyrosine supplementation among school-aged children with phenylketonuria","volume":"146","author":"Mazzocco","year":"1992","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0195","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0022-3476(95)70031-5","article-title":"Effect of high-dose tyrosine supplementation on brain function in adults with phenylketonuria","volume":"127","author":"Pietz","year":"1995","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0200","first-page":"417","article-title":"Case studies of the effect of tyrosine administration in children with phenylketonuria on cognitive processes","volume":"204","author":"Wasser","year":"1992","journal-title":"Klin. Padiatr."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0205","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1651-2227.1987.tb10521.x","article-title":"Increased vigilance and dopamine synthesis by large doses of tyrosine or phenylalanine restriction in phenylketonuria","volume":"76","author":"Lou","year":"1987","journal-title":"Acta Paediatr. Scand."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0210","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"American College of Medical Genetics and Genomics Therapeutics Committee, phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"issue":"Suppl","key":"10.1016\/j.ymgme.2021.11.003_bb0215","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.ymgme.2013.08.013","article-title":"Neurocognitive functioning in adults with phenylketonuria: results of a long term study","volume":"110","author":"Weglage","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2021.11.003_bb0220","article-title":"Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria","volume":"1\u201312","author":"Boot","year":"2017","journal-title":"Psychol. Med."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221008210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719221008210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:50:49Z","timestamp":1761090649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719221008210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1096719221008210"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.11.003","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The increasing importance of LNAA supplementation in phenylketonuria at higher plasma phenylalanine concentrations","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}